Briviact Approval Expanded to Include Younger Patients with Partial-Onset Seizures
Briviact is now indicated for the treatment of partial-onset seizures in patients 1 month of age and older.
Seizure Disorders
Evidence to Support Suicidality Warning for Newer Antiseizure Meds Lacking
The analysis included 5 antiseizure medications (eslicarbazepine, perampanel, brivaracetam, cannabidiol, and cenobamate) evaluated in 17 randomized clinical trials.
Lithium Compared With Newer Therapies as Adjunct to Antidepressants
The likelihood of help or harm, also known as the risk/benefit ratio, was found to be more favorable for lithium.
Buccal Film Formulation of Diazepam to Get FDA Review
Libervant is a buccally administered soluble film of diazepam.
First-of-its-Kind Deep Brain Stimulation Directional Lead Approved
The system works with Medtronic’s Percept™ PC Neurostimulator.
Neonates With Acute Seizures May Be Overmedicated
Those discontinuing seizure meds after symptom resolution in the hospital have same neurodevelopment, epilepsy outcomes at 24 months
FDA: Risk of Arrhythmias With Lamotrigine in Patients With Heart Disease
Lamotrigine is indicated as monotherapy or adjunctive therapy for epilepsy and for use as maintenance treatment in patients with bipolar I disorder.
Fetal Exposure to Antiseizure Meds Has No Neuropsychological Impact
No difference found in primary outcome of Verbal Index score at age 3 years with fetal exposure to ASM or for those born to healthy women
Vimpat Approved for Primary Generalized Tonic-Clonic Seizures
The FDA also approved Vimpat Injection for use in pediatric patients 4 years of age and older.
Room Temperature Stable Fosphenytoin Gets FDA Approval
The product is a ready-to-dilute, room temperature stable formulation of fosphenytoin for IV injection, which allows for point-of-care storage.
